论文部分内容阅读
目的:探讨中药复方固本防哮饮对哮喘易感基因血清类黏蛋白1样蛋白3(ORMDL3)蛋白表达的干预作用。方法:体内实验中,以卵蛋白(OVA)致敏小鼠为动物模型;体外实验中,以白介素-4(IL-4)和白介素-13(IL-13)刺激人胚肺成纤维细胞(MRC-5)为细胞模型,分别以固本防哮饮及其含药血清进行干预,通过肺组织病理评分评价动物造模用药前后的差异,Western Blot检测肺组织中及MRC-5细胞中ORMDL3蛋白含量的改变。结果:体内实验中,固本防哮饮能明显减轻肺组织气道炎性浸润(P<0.05),且显著下调ORMDL3蛋白的表达(P<0.05);体外实验中,固本防哮饮含药血清可下调MRC-5中ORMDL3蛋白表达(P<0.05)。结论:固本防哮饮改善哮喘患儿体质状态的药理机制之一可能在于调节易感基因ORMDL3蛋白的表达,从而有效减轻炎症反应,达到预防哮喘发作的目的。
Objective: To investigate the intervention effect of Guben anti-asthma drink on the protein expression of the susceptible gene serm-like mucin-like protein 3 (ORMDL3) in asthma. Methods: In vivo experiments, the ovalbumin (OVA) -induced mice were used as animal models. In vitro experiments, human embryonic lung fibroblasts were stimulated with interleukin-4 and interleukin-13 MRC-5) were used as the cell model to observe the effects of Guben anti-asthma drink and its medicated serum respectively. The lung histopathological score was used to evaluate the difference of animal model before and after treatment. The expression of ORMDL3 in lung tissue and MRC-5 cells was detected by Western Blot Changes in protein content. Results: In vivo, Guben anti-asthma drink can significantly reduce lung tissue airway inflammatory infiltration (P <0.05), and significantly down-regulated ORMDL3 protein expression (P <0.05); in vitro experiments, Serum of serum could down-regulate ORMDL3 protein expression in MRC-5 (P <0.05). Conclusion: One of the pharmacological mechanisms of Guben anti-asthma drink in improving the physique state of children with asthma may be to regulate the expression of ORMDL3 gene in susceptible genes so as to effectively reduce the inflammatory reaction and achieve the purpose of preventing asthma attacks.